GlassScriptPhysician profile
Anait Galfaian
NPI 1447358981
$8,705.55
in general payments reported to CMS, 2019-2025
23 companies · $1,393 in 2025
The $1,393 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,874 · 2020: $731 · 2021: $1,208 · 2022: $2,066 · 2023: $877 · 2024: $557 · 2025: $1,393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,826.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,329.48 | 2019-2025 | Evenity, Repatha, Repatha |
| Novo Nordisk INC | $1,322.43 | 2019-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $1,187.11 | 2019-2022 | |
| Amarin Pharma, INC. | $771.08 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $506.78 | 2022 | |
| Janssen Pharmaceuticals, INC | $502.45 | 2019-2021 | |
| Glaxosmithkline, LLC. | $414.99 | 2020-2025 | Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $338.08 | 2022-2025 | Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $282.51 | 2019-2023 | Jardiance |
| Abbvie INC. | $232.63 | 2021-2023 | |
| Ironwood Pharmaceuticals, INC | $221.87 | 2020-2022 | |
| Optinose US, INC. | $126.86 | 2024 | |
| Idorsia Pharmaceuticals US INC | $125.00 | 2023 | Quviviq |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $100.45 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.03 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $37.79 | 2019 | |
| Sumitomo Pharma America, INC. | $29.57 | 2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $26.10 | 2021 | |
| Medtronic Vascular, INC. | $24.87 | 2019 | |
| Sunovion Pharmaceuticals INC. | $22.05 | 2019 | |
| Pfizer INC. | $16.65 | 2019 | |
| Ardelyx, INC. | $14.07 | 2025 | Ibsrela |
| Kowa Pharmaceuticals America, INC. | $13.70 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anait Galfaian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.